Skip to main navigation Skip to search Skip to main content

Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP

  • Maria Kyrgiou
  • , Antonios Athanasiou
  • , Marc Arbyn
  • , Sigurd F. Lax
  • , Maria Rosaria Raspollini
  • , Pekka Nieminen
  • , Xavier Carcopino
  • , Jacob Bornstein
  • , Murat Gultekin
  • , Evangelos Paraskevaidis

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations

Abstract

Local cervical treatment for squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) removes or ablates a cone-shaped or dome-shaped part of the cervix that contains abnormal cells. This Series paper introduces the 2022 terminology for cone dimensions after local conservative treatment for SIL, CIN, or early invasive cervical cancer. The terminology was prepared by the Nomenclature Committee of the European Society of Gynaecologic Oncology, the European Federation for Colposcopy, the International Federation of Cervical Pathology and Colposcopy, and the European Society of Pathology. Cone length should be tailored to the type of transformation zone. Treatment of SIL or CIN is associated with an increased risk of preterm birth, which escalates with increasing cone length. There is a lack of agreement regarding terms used to report excised specimen dimensions both intraoperatively and in the pathology laboratory. Consensus is needed to make studies addressing effectiveness and safety of SIL or CIN treatment comparable, and to facilitate their use to improve accuracy of antenatal surveillance and management. This Series paper summarises the current terminology through a review of existing literature, describes new terminology as agreed by a group of experts from international societies in the field of cervical cancer prevention and treatment, and recommends use of the new terminology that will facilitate communication between clinicians and foster more specific treatment guidelines that balance obstetrical harm against therapeutic effectiveness.

Original languageEnglish
Pages (from-to)e385-e392
JournalThe Lancet Oncology
Volume23
Issue number8
DOIs
StatePublished - Aug 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Ltd

Funding

This work has been funded by ESGO and EFC (P78368). MK and AA were funded by the National Institute for Health and Care Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0816-20004). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. MA was also supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission through the Risk-based Screening for Cervical Cancer Network (847845), and by ESGO.

FundersFunder number
ESGO
Horizon 2020 Framework Programme for Research and Innovation of the European Commission847845
Europe for CitizensP78368
National Institute for Health and Care Research
Research for Patient Benefit ProgrammePB-PG-0816-20004

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP'. Together they form a unique fingerprint.

    Cite this